TPM502 / Topas Therap - LARVOL DELTA

TPM502, A TOLERIZING NANOPARTICLE MIXTURE FOR CELIAC DISEASE TREATMENT, INDUCES LONG-LASTING PHENOTYPIC CHANGES IN HLA-DQ2.5-GLIADIN-SPECIFIC TETRAMER+ CD4+ T CELLS, INDICATING ANTIGEN-SPECIFIC IMMUNOMODULATORY EFFECTS (UEGW 2025) - P1/2 | "Data from the first longitudinal tetramer-based flow cytometry analysis in CeD patients provide evidence that TPM502 induces antigen-specific tolerance through T-cell immunomodulation. These results corroborate other pharmacodynamic outcomes generated in this study, including a significant and dose-dependent reduction in ex vivo IL-2 and IFN-γ secretion by gluten-specific T cells after treatment. In addition to a good safety and tolerability profile of TPM502, this nanoparticle-mediated induction of antigen-specific tolerance may provide a novel therapeutic avenue to treat celiac disease."

Immunomodulating • IO biomarker • Celiac Disease • Immunology • CD38 • CD4 • CD8 • ENTPD1 • ICOS • IFNG • IL2 • IL2RA • IL7R • TIGIT

SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF TPM502, A MIXTURE OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF CELIAC DISEASE (CED) (DDW 2025) - P1/2 | No abstract available

Clinical • PK/PD data • Celiac Disease • Immunology

SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF TPM502, A MIXTURE OF TOLERIZING NANOPARTICLES FOR THE TREATMENT OF CELIAC DISEASE (CED) (DDW 2025) - No abstract available

Clinical • PK/PD data • Celiac Disease • Immunology

A Study to Assess the Safety of TPM502 in Adults With Celiac Disease (clinicaltrials.gov) - P2 | N=38 | Completed | Sponsor: Topas Therapeutics GmbH | Recruiting ➔ Completed

Trial completion • Celiac Disease • Immunology • IL2 • TGM2

A Study to Assess the Safety of TPM502 in Adults With Celiac Disease (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: Topas Therapeutics GmbH | Phase classification: P2a ➔ P2

Phase classification • Celiac Disease • Immunology • IL2 • TGM2

A placebo-controlled study to evaluate the safety, tolerability, biochemical and physiologic effects of two infusions of escalating doses of TPM502 in adults diagnosed with celiac disease (clinicaltrialsregister.eu) - P1/2 | N=42 | Ongoing | Sponsor: Topas Therapeutics GmbH

New P1/2 trial • Celiac Disease • Gastroenterology • Immunology • IL2 • TGM2

A Study to Assess the Safety of TPM502 in Adults With Celiac Disease (clinicaltrials.gov) - P2a | N=42 | Recruiting | Sponsor: Topas Therapeutics GmbH

New P2a trial • Celiac Disease • Immunology • IL2 • TGM2